Brief: Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson
25/06/2025 14:03
June 25 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY-STAGE CLINICAL DATA FOR NEXT-GENERATION WEE1 INHIBITOR, APR-1051, IN HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN COLLABORATION WITH MD ANDERSON CANCER CENTER APREA THERAPEUTICS INC - PHASE 1 UPDATE SHOWS EARLY DISEASE CONTROL IN HPV+ PATIENT Source text: ID:nGNXbt7Z3h Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing